Clinical Pharmacy and Biopharmacy- Conference Papers

Permanent URI for this collection

https://ir.unilag.edu.ng/handle/123456789/3746

Browse

Browsing Clinical Pharmacy and Biopharmacy- Conference Papers by Subject "Adult patients"

Now showing 1 - 1 of 1
  • Item
    Open Access
    Profile of Adverse Effects reported by Patients on Highly Active Antiretroviral Therapy (HAART) in a Treatment Site in Lagos, Nigeria
    (2009-04) Herbertson, E.; Tayo, F.; Aderemi-Williams, R.I.; Ezechi, O.; Odunukwe, N.
    Background: Funded treatment program provided by international donors have in recent years improved the quality of life of people living with HIV/AIDS (PLWHA) in Nigeria. This benefit of highly active antiretroviral therapy (HAART) has also been associated with some adverse drug reactions (ADRs). The study aimed to identify types of adverse effects being experienced by patients vis-a-vis some demographic characteristics. Method: A retrospective study was done of adult patients' case files and pharmacy ADR data collated from 2002 to 2007. Results: A total of 191 cases of reported ADRs were obtained from 4,313 patient case files, 9 cases were excluded due to incomplete data. Analysis showed more ADRs reported by females 115 (63.2%) than males, 67 (36.8%). The mean ages for the males and females respondents were 43 and 38.5 years. respectively. 21 types of ADRs were identified. The most frequently reported ADRs were lipodystrophy, 59 (9 males, 50 females); peripheral neuropathy, 48 (26 males, 22 females); central nervous system (CNS) effects, 15 (10 males,S females); and rash/itching, 13 (5 males. 8 females). The age range most affected by lipodystrophy and peripheral neuropathy in both sex was 36 to 45 years (6 males, 22 females and 15 males, 13 females. respectively). Both of these ADRs were reported by patients on a nevirapine (NVp)namivudine (3TC)/stavudine (d4T) HAART combination. The same age range in both sexes also reported incidence of CNS adverse effects with almost all (14) on an efavirenz (EFV)I3TCld4T combination; only 1 was on a NVP/tenofovir (TDF)/emtricitabine (FTC) combination. Rashes and itching was experienced among patients within the age range of 20 to 45 with most (13) on NVP/3TCld4T combination with one patient on NVP/3TClabacavir (ABC) combination. Conclusions: Observed ADRs were similar to reported ADRs. Age range most affected was 36 to 45 years.